MedTrace Logo

Drug Monitoring of Antibiotics in Critical Care Patients

NCT01793012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2020-09-02

No results posted yet for this study

Summary

Infections are critical factors for the survival of critically ill patients. A broad, high-dose and early initial therapy of antibiotics is of particular relevance.

A serious problem is the high variability of antibiotic serum concentrations after administration of antibiotics in patients of the critical care units. This may result in the risk of underdosage with possible ineffective therapeutic levels as well as in the risk of overdosage with possible adverse and toxic effects. The goal of this study is to determine antibiotic concentrations in blood and to evaluate concentrations with the course of the therapy. The measurement of antibiotic concentrations in blood may allow an individual adaption of the dose in future.

100 - 200 patients will be included in this study. Only critically ill patients of the ICU of the Department of Anaesthesiology will be included that receive one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, and colistin.

Conditions

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Bernhard Zwissler, Prof.Dr.med. · Department of Anaesthesiology of the University Hospital of Munich

  • Daniel Teupser, Prof.Dr.med. · Institute of Laboratory Medicine of the University Hospital of Munich

  • Johannes Zander, Dr. med. · Institute of Laboratory Medicine of the University Hospital of Munich

  • Michael Zoller, Dr. med. · Department of Anaesthesiology of the University Hospital of Munich

  • Lorenz Frey, Dr. med. · Department of Anaesthesiology of the University Hospital of Munich

  • Michael Vogeser, Prof.Dr.med. · Institute of Laboratory Medicine of the University Hospital of Munich

  • Mathias Bruegel, Dr. med. · Institute of Laboratory Medicine of the University Hospital of Munich

  • Lesca Holdt, Dr.rer.nat. · Institute of Laboratory Medicine of the University Hospital of Munich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793012 on ClinicalTrials.gov